{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:56:54Z","timestamp":1777521414150,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To examine the long-term visual outcomes after initial treatment with combined photodynamic therapy (PDT) or aflibercept treat-and-extend (TAE) monotherapy in patients with pachychoroid neovasculopathy (PNV).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients diagnosed with PNV, initially treated with PDT combined with anti-vascular endothelial growth factor (VEGF) or intravitreal aflibercept (IVA) monotherapy in the TAE protocol and followed up for at least 6\u00a0months, were included in the study. Medical records were retrospectively reviewed. Survival analysis was performed, in which deterioration in logMAR visual acuity by 0.1 or 0.3 is defined as \u201cdeath.\u201d The annual number of treatments was also analyzed. Sub-analysis was performed on 33 patients diagnosed with PNV without polypoidal lesions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This study included 46 patients (23 in the initial combined PDT group and 23 in the IVA TAE group). Mean age, sex, mean baseline logMAR visual acuity, or duration of observation (3.6\u2009\u00b1\u20093.2\u00a0years vs. 3.1\u2009\u00b1\u20091.9\u00a0years) in both groups were comparable. As for visual outcome, no significant differences were found in survival analysis based on worsening of 0.1 or 0.3 logMAR (3-year survival; 26% vs. 26%, 91% vs. 90%, respectively). Meanwhile, the additional number of anti-VEGF injections per year was significantly lower in the initial combined PDT group than in the IVA TAE group (1.0\u2009\u00b1\u20091.3 vs. 4.1\u2009\u00b1\u20091.5, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). No significant differences were found in the number of additional PDTs per year (0.07\u2009\u00b1\u20090.20 vs. 0.02\u2009\u00b1\u20090.09, p\u2009=\u20090.27). Similar results were found in a sub-analysis of 33 patients without polyps.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the treatment of PNV, regardless of the presence of polyps, the long-term visual outcomes were similar between the initial combined PDT and IVA TAE monotherapy. However, the annual number of anti-VEGF injections was lower in the initial combined PDT group than in the aflibercept TAE group, whereas that of PDT was comparable.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-024-06387-z","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T12:02:44Z","timestamp":1706702564000},"page":"1811-1818","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes"],"prefix":"10.1007","volume":"262","author":[{"given":"Nobuya","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichiro","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohdai","family":"Kitamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1762-0797","authenticated-orcid":false,"given":"Ryo","family":"Obata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"6387_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","volume":"35","author":"CE Pang","year":"2015","unstructured":"Pang CE, Freund KB (2015) Pachychoroid neovasculopathy. Retina 35:1\u20139. https:\/\/doi.org\/10.1097\/IAE.0000000000000331","journal-title":"Retina"},{"key":"6387_CR2","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1097\/IAE.0b013e3182680a66","volume":"32","author":"AT Fung","year":"2012","unstructured":"Fung AT, Yannuzzi LA, Freund KB (2012) Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 32:1829\u20131837. https:\/\/doi.org\/10.1097\/IAE.0b013e3182680a66","journal-title":"Retina"},{"key":"6387_CR3","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444. https:\/\/doi.org\/10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"key":"6387_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"6387_CR5","doi-asserted-by":"publisher","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C\u00a0Erfurth US; VIEW 1 and VIEW2 Study Groups (2012) Intravitreal aflibercept (VEGF Trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"6387_CR6","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, Investigators ALTAIR (2020) Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther 37:1173\u20131187. https:\/\/doi.org\/10.1007\/s12325-020-01236-x","journal-title":"Adv Ther"},{"key":"6387_CR7","first-page":"198","volume":"119","author":"Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group","year":"2001","unstructured":"Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of two randomized clinical trials\u2014TAP Report 2. Arch Ophthalmol 119:198\u2013207","journal-title":"Arch Ophthalmol"},{"key":"6387_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","author":"Verteporfin In Photodynamic Therapy Study Group","year":"2001","unstructured":"Verteporfin In Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization\u2013verteporfin in photodynamic therapy Report 2. Am J Ophthalmol 131:541\u2013560. https:\/\/doi.org\/10.1016\/S0002-9394(01)00967-9","journal-title":"Am J Ophthalmol"},{"key":"6387_CR9","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32:1453\u20131464. https:\/\/doi.org\/10.1097\/IAE.0b013e31824f91e8","journal-title":"Retina"},{"key":"6387_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ajo.2012.07.018","volume":"155","author":"H Koizumi","year":"2013","unstructured":"Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S (2013) Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability. Am J Ophthalmol 155:305-313.e1. https:\/\/doi.org\/10.1016\/j.ajo.2012.07.018","journal-title":"Am J Ophthalmol"},{"key":"6387_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10384-018-0562-0","volume":"62","author":"H Matsumoto","year":"2018","unstructured":"Matsumoto H, Hiroe T, Morimoto M, Mimura K, Ito A, Akiyama H (2018) Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol 62:144\u2013150. https:\/\/doi.org\/10.1007\/s10384-018-0562-0","journal-title":"Jpn J Ophthalmol"},{"key":"6387_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10384-015-0387-z","volume":"59","author":"Y Nomura","year":"2015","unstructured":"Nomura Y, Yanagi Y (2015) Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability. Jpn J Ophthalmol 59:261\u2013265. https:\/\/doi.org\/10.1007\/s10384-015-0387-z","journal-title":"Jpn J Ophthalmol"},{"key":"6387_CR13","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.ajo.2013.07.001","volume":"156","author":"HJ Cho","year":"2013","unstructured":"Cho HJ, Kim HS, Jang YS, Han J, Lew YJ, Lee TG, Kim CG, Kim JW (2013) Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Am J Ophthalmol 156:1192-1200.e1. https:\/\/doi.org\/10.1016\/j.ajo.2013.07.001","journal-title":"Am J Ophthalmol"},{"key":"6387_CR14","doi-asserted-by":"publisher","first-page":"8337","DOI":"10.1038\/s41598-020-65346-w","volume":"10","author":"K Azuma","year":"2020","unstructured":"Azuma K, Okubo A, Nomura Y, Zhou H, Terao R, Hashimoto Y, Asano KS, Azuma K, Inoue T, Obata R (2020) Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy. Sci Rep 10:8337. https:\/\/doi.org\/10.1038\/s41598-020-65346-w","journal-title":"Sci Rep"},{"key":"6387_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10384-020-00722-7","volume":"64","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Mukai R, Kikuchi Y, Morimoto M, Akiyama H (2020) One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions. Jpn J Ophthalmol 64:203\u2013209. https:\/\/doi.org\/10.1007\/s10384-020-00722-7","journal-title":"Jpn J Ophthalmol"},{"key":"6387_CR16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00417-020-04661-4","volume":"258","author":"Y Kitajima","year":"2020","unstructured":"Kitajima Y, Maruyama-Inoue M, Ito A, Sato S, Inoue T, Yamane S, Kadonosono K (2020) One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol 258:1279\u20131285. https:\/\/doi.org\/10.1007\/s00417-020-04661-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6387_CR17","doi-asserted-by":"publisher","first-page":"e0248760","DOI":"10.1371\/journal.pone.0248760","volume":"16","author":"A Miki","year":"2021","unstructured":"Miki A, Kusuhara S, Otsuji T, Kawashima Y, Miki K, Imai H, Nakamura M, Tsujikawa A (2021) Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PLoS ONE 16:e0248760. https:\/\/doi.org\/10.1371\/journal.pone.0248760","journal-title":"PLoS ONE"},{"key":"6387_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3390\/ph15040483","volume":"15","author":"MS Akushichi","year":"2022","unstructured":"Akushichi MS, Ono S, Taneda T, Klose G, Sasamori A, Song Y (2022) One-year outcome of combination therapy with full or reduced photodynamic therapy and one anti-vascular endothelial growth factor in pachychoroid neovasculopathy. Pharmaceuticals (Basel) 15:483. https:\/\/doi.org\/10.3390\/ph15040483","journal-title":"Pharmaceuticals (Basel)"},{"key":"6387_CR19","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1097\/IAE.0000000000001758","volume":"38","author":"Y Yanagi","year":"2018","unstructured":"Yanagi Y, Ting DSW, Ng WY, Lee SY, Mathur R, Chan CM, Yeo I, Wong TY, Cheung GCM (2018) Choroidal vascular hyperpermeability as a predictor of treatment response for polypoidal choroidal vasculopathy. Retina 38:1509\u20131517. https:\/\/doi.org\/10.1097\/IAE.0000000000001758","journal-title":"Retina"},{"key":"6387_CR20","doi-asserted-by":"publisher","unstructured":"Kawai K, Miyata M, Ooto S, Tamura H, Ueda-Arakawa N, Takahashi A, Uji A, Muraoka Y, Miyake M, Yamashiro K, Tsujikawa A (2022) Macular atrophy at 5 years after photodynamic therapy for polypoidal choroidal vasculopathy. Eye 37(6):1067\u20131072.\u00a0https:\/\/doi.org\/10.1038\/s41433-022-02067-6","DOI":"10.1038\/s41433-022-02067-6"},{"key":"6387_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/bjophthalmol-2018-311963","volume":"103","author":"M Miyata","year":"2019","unstructured":"Miyata M, Ooto S, Yamashiro K, Tamura H, Hata M, Ueda-Arakawa N, Yoshikawa M, Numa S, Tsujikawa A (2019) Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. Br J Ophthalmol 103:617\u2013622. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-311963","journal-title":"Br J Ophthalmol"},{"key":"6387_CR22","doi-asserted-by":"publisher","first-page":"16248","DOI":"10.1038\/s41598-020-73303-w","volume":"10","author":"M Tagawa","year":"2020","unstructured":"Tagawa M, Ooto S, Yamashiro K, Tamura H, Oishi A, Miyata M, Hata M, Yoshikawa M, Yoshimura N, Tsujikawa A (2020) Characteristics of pachychoroid neovasculopathy Sci Rep 10:16248. https:\/\/doi.org\/10.1038\/s41598-020-73303-w","journal-title":"Characteristics of pachychoroid neovasculopathy Sci Rep"},{"key":"6387_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ajo.2010.10.030","volume":"151","author":"I Maruko","year":"2011","unstructured":"Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T (2011) Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 151:594-603.e1. https:\/\/doi.org\/10.1016\/j.ajo.2010.10.030","journal-title":"Am J Ophthalmol"},{"key":"6387_CR24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"Lim TH, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Lee WK, Cheung CMG, Ngah NF, Patalauskaite R, Margaron P, Koh A; EVEREST II Study Group","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Lee WK, Cheung CMG, Ngah NF, Patalauskaite R, Margaron P, Koh A; EVEREST II Study Group (2020) Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol 138:935\u2013942. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2443","journal-title":"JAMA Ophthalmol"},{"key":"6387_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00417-016-3467-y","volume":"255","author":"W Kikushima","year":"2017","unstructured":"Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H (2017) Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 255:311\u2013316. https:\/\/doi.org\/10.1007\/s00417-016-3467-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6387_CR26","doi-asserted-by":"publisher","first-page":"12052","DOI":"10.1038\/s41598-021-91589-2","volume":"11","author":"J Yoon","year":"2021","unstructured":"Yoon J, Yoon W, Na S, kwan, Lee J, Kim CG, Kim JW, Cho HJ, (2021) Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. Sci Rep 11:12052. https:\/\/doi.org\/10.1038\/s41598-021-91589-2","journal-title":"Sci Rep"},{"issue":"2","key":"6387_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ajo.2014.10.035","volume":"159","author":"HJ Cho","year":"2015","unstructured":"Cho HJ, Yoo SG, Kim HS, Kim JH, Kim CG, Lee TG, Kim JW (2015) Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol 159(2):285\u201392.e1. https:\/\/doi.org\/10.1016\/j.ajo.2014.10.035","journal-title":"Am J Ophthalmol"},{"key":"6387_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2147\/OPTH.S386222","volume":"17","author":"T Miyakubo","year":"2023","unstructured":"Miyakubo T, Mukai R, Matsumoto H, Morimoto M, Takahashi M, Nagai K, Nakamura K, Hoshino J, Akiyama H (2023) Comparison of the 2-year results of photodynamic therapy with aflibercept and aflibercept monotherapy for polypoidal choroidal vasculopathy. Clin Ophthalmol 17:571\u2013577","journal-title":"Clin Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06387-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06387-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06387-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T03:35:20Z","timestamp":1716262520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06387-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["6387"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06387-z","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"22 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of Tokyo Faculty of Medicine (#2217).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Ryo Obata has received honoraria for speaking and consulting from Santen, Bayer, Novartis, Chugai, Senju, and Boehringer Ingelheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}